SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE
OF SEGMENT INFORMATION
|
|
2023 |
|
|
2022 |
|
|
|
For
the Three Months Ended
January
31,
|
|
|
|
2023 |
|
|
2022 |
|
Net
loss: |
|
|
|
|
|
|
|
|
CAR-T
Therapeutics |
|
$ |
(911 |
) |
|
$ |
(1,611 |
) |
Cancer
Vaccines |
|
|
(958 |
) |
|
|
(1,357 |
) |
Anti-Viral
Therapeutics |
|
|
(482 |
) |
|
|
(904 |
) |
Other |
|
|
(3 |
) |
|
|
(7 |
) |
Total |
|
$ |
(2,354 |
) |
|
$ |
(3,879 |
) |
Net Loss |
|
$ |
(2,354 |
) |
|
$ |
(3,879 |
) |
|
|
|
|
|
|
|
|
|
Total
operating costs and expenses |
|
$ |
2,556 |
|
|
$ |
3,880 |
|
Less
non-cash share-based compensation |
|
|
(1,063 |
) |
|
|
(2,354 |
) |
Operating
costs and expenses excluding non-cash share-based compensation |
|
$ |
1,493 |
|
|
$ |
1,526 |
|
Operating
costs and expenses excluding non-cash share based compensation expense: |
|
|
|
|
|
|
|
|
CAR-T
Therapeutics |
|
$ |
598 |
|
|
$ |
669 |
|
Cancer
Vaccines |
|
|
588 |
|
|
|
480 |
|
Anti-Viral
Therapeutics |
|
|
305 |
|
|
|
372 |
|
Other |
|
|
2 |
|
|
|
5 |
|
Total |
|
$ |
1,493 |
|
|
$ |
1,526 |
|
Operating
costs and expenses excluding non-cash based compensation |
|
$ |
1,493 |
|
|
$ |
1,526 |
|
|
|
|
|
|
|
|
|
|
|
|
January
31, 2023 |
|
|
October
31, 2022 |
|
Total
assets: |
|
|
|
|
|
|
|
|
CAR-T
Therapeutics |
|
$ |
11,318 |
|
|
$ |
16,921 |
|
Cancer
Vaccines |
|
|
11,098 |
|
|
|
9,442 |
|
Anti-Viral
Therapeutics |
|
|
5,750 |
|
|
|
3,811 |
|
Other |
|
|
140 |
|
|
|
238 |
|
Total |
|
$ |
28,306 |
|
|
$ |
30,412 |
|
Total assets |
|
$ |
28,306 |
|
|
$ |
30,412 |
|
|